ClinicalTrials.gg

Program

Torsemide

Also written as “Torasemide tablet 10 mg”, “torasemide” and “torsemide”.

Its studies are mostly in Heart Failure · Edema · Body Weight Changes · Hypertension · Diabetes Mellitus, Type 2, led by 5 companies.

Furthest: phase 4, since Nov 24, 202411 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sarfez Pharmaceuticals40 open or runningphase 4since Nov 24, 2024Apr 17, 2018none ahead
Ferrer Internacional20 open or runningphase 4since Jun 6, 2006Jun 6, 2006none ahead
Hikma Pharmaceuticals20 open or runningno phasesince Jan 15, 2008Jan 15, 2008none ahead
Par Health20 open or runningphase 1since Apr 1, 2008Apr 1, 2008none ahead
Menarini Group11 open or runningphase 1since Sep 10, 2025Sep 10, 2025none ahead

Also a collaborator on its studies: anapharm.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 6, 2006First study: phase 4 study in HypertensionNew to Ferrer InternacionalFerrer Internacional · NCT00334386 · 388 enrolled
  2. Dec 11, 2006Phase 4 study in Heart FailureFerrer Internacional · NCT00409942 · 142 enrolled · Spain
  3. Jan 15, 2008Hikma Pharmaceuticals's first studies: 2 no phase studies in EdemaNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT00602615, NCT00602303
  4. Apr 1, 2008Par Health's first studies: 2 phase 1 studiesNew to Par HealthPar Health · NCT00654043, NCT00653549
  5. Apr 17, 2018Sarfez Pharmaceuticals's first study: phase 1 study in Body Weight ChangesNew to Sarfez PharmaceuticalsSarfez Pharmaceuticals · NCT03509545 · 20 enrolled · India
  6. Nov 24, 2024Phase 4 study in Heart FailureSarfez Pharmaceuticals · NCT06708611 · United States
  7. Jun 3, 20252 phase 3 studiesSarfez Pharmaceuticals · NCT07015671, NCT07046975
  8. Sep 10, 2025Menarini Group's first study: phase 1 study in Healthy Adult Male and Female VolunteersNew to Menarini GroupMenarini Group · NCT07201584 · 26 planned · Kazakhstan

TargetBeta

SLC12A1 →read by rule
“Sodium-(potassium)-chloride cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC12A1

ProgramCompanyFurthest phaseStudies
FurosemideruleBoehringer Ingelheimphase 427

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07201584Healthy Adult Male and Female Volunteers · Kazakhstan1RecruitingMenarini GroupDec 30, 202526
NCT07046975Bioavailability Heathy Volunteers · United States3CompletedSarfez PharmaceuticalsFeb 28, 202624
NCT07015671Bioequivalence Study in Healthy Subjects · United States3CompletedSarfez PharmaceuticalsDec 30, 202524
NCT06708611Heart Failure · United States4WithdrawnSarfez PharmaceuticalsMar 25, 20250
NCT03509545Body Weight Changes · India1TerminatedSarfez PharmaceuticalsJun 30, 202220
NCT00654043Lecithin Cholesterol Acyltransferase Deficiency1CompletedPar HealthMay 200124
NCT00653549Fasting1CompletedPar HealthMay 200126
NCT00602615Edema · United States–CompletedHikma PharmaceuticalsSep 200328
NCT00602303Edema · United States–CompletedHikma PharmaceuticalsSep 200328
NCT00409942Heart Failure · Spain4CompletedFerrer InternacionalJun 2009142
NCT00334386Hypertension4CompletedFerrer Internacional388

How it is read

Names in the registry

  • “Torsemide”, 4 entries
  • “Torasemide tablet 10 mg”, 2 entries
  • “torasemide”, 2 entries
  • “torsemide”, 1 entry
  • “CHF Patients: ER Torsemide 40 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.